| iShares 0-3 Month Treasury Bond ETF | 700K | US$70.5M | 48.3% |
| State Street SPDR S&P Biotech ETF | 387K | US$60.9M | 41.8% |
| Sera Prognostics, Inc. | 2.4M | US$5.01M | 3.4% |
| Halozyme Therapeutics, Inc. | 3,000 | US$331K | 0.23% |
| Madrigal Pharmaceuticals, Inc. | 600 | US$302K | 0.21% |
| Exelixis, Inc. | 5,000 | US$292K | 0.20% |
| Argenx Se | 300 | US$288K | 0.20% |
| Nurix Therapeutics, Inc. | 12,000 | US$285K | 0.20% |
| Tg Therapeutics, Inc. | 5,000 | US$279K | 0.19% |
| Tarsus Pharmaceuticals, Inc. | 3,500 | US$275K | 0.19% |
| Harmony Biosciences Holdings, Inc. | 7,000 | US$275K | 0.19% |
| Arcutis Biotherapeutics, Inc. | 10,000 | US$264K | 0.18% |
| Supernus Pharmaceuticals, Inc. | 6,000 | US$258K | 0.18% |
| Immunome, Inc. | 12,000 | US$258K | 0.18% |
| Neurocrine Biosciences, Inc. | 1,800 | US$255K | 0.18% |
| Oruka Therapeutics, Inc. | 3,000 | US$250K | 0.17% |
| Tango Therapeutics, Inc. | 10,000 | US$250K | 0.17% |
| Definium Therapeutics, Inc. | 6,500 | US$247K | 0.17% |
| Revolution Medicines, Inc. | 1,200 | US$246K | 0.17% |
| Aurinia Pharmaceuticals Inc | 15,000 | US$243K | 0.17% |
| Incyte Corporation | 2,000 | US$243K | 0.17% |
| Intellia Therapeutics, Inc. | 20,000 | US$241K | 0.17% |
| Immunovant, Inc. | 7,000 | US$236K | 0.16% |
| Stoke Therapeutics, Inc. | 9,000 | US$234K | 0.16% |
| Krystal Biotech, Inc. | 692 | US$230K | 0.16% |
| Syndax Pharmaceuticals, Inc. | 12,000 | US$226K | 0.15% |
| Kymera Therapeutics, Inc. | 2,000 | US$224K | 0.15% |
| Dianthus Therapeutics, Inc. | 2,500 | US$220K | 0.15% |
| Trevi Therapeutics, Inc. | 15,000 | US$215K | 0.15% |
| Mirum Pharmaceuticals, Inc. | 2,500 | US$214K | 0.15% |
| Immunocore Holdings Plc | 7,000 | US$212K | 0.15% |
| Protagonist Therapeutics, Inc. | 1,500 | US$211K | 0.14% |
| Edgewise Therapeutics, Inc. | 5,000 | US$203K | 0.14% |
| Oric Pharmaceuticals, Inc. | 13,000 | US$175K | 0.12% |
| Dyne Therapeutics, Inc. | 10,000 | US$161K | 0.11% |
| COMPASS Pathways Plc | 10,000 | US$124K | 0.09% |
| Ocular Therapeutix, Inc. | 15,000 | US$115K | 0.08% |
| Cytomx Therapeutics, Inc. | 39,400 | US$107K | 0.07% |
| Ardelyx, Inc. | 30,000 | US$103K | 0.07% |
| Olema Pharmaceuticals, Inc. | 10,000 | US$86,400 | 0.06% |
| Acadia Pharmaceuticals Inc. | 0 | US$0 | 0.00% |
| Alnylam Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Amylyx Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Arrivent Biopharma, Inc. | 0 | US$0 | 0.00% |
| Arrowhead Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Axsome Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Bridgebio Pharma, Inc. | 0 | US$0 | 0.00% |
| Celldex Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Cogent Biosciences, Inc. | 0 | US$0 | 0.00% |
| Crinetics Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Denali Therapeutics Inc. | 0 | US$0 | 0.00% |
| Disc Medicine, Inc. | 0 | US$0 | 0.00% |
| Enliven Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Eyepoint, Inc. | 0 | US$0 | 0.00% |
| Ionis Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Kodiak Sciences Inc | 0 | US$0 | 0.00% |
| Liquidia Corporation | 0 | US$0 | 0.00% |
| Monte Rosa Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Ptc Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Rapport Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Rhythm Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Scholar Rock Holding Corporation | 0 | US$0 | 0.00% |
| Spyre Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Ultragenyx Pharmaceutical Inc. | 0 | US$0 | 0.00% |
| Vera Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Viking Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Xenon Pharmaceuticals Inc. | 0 | US$0 | 0.00% |
| Zymeworks Inc. | 0 | US$0 | 0.00% |